An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with ...

In a small Phase II trial, people with cocaine use disorder who took mavoglurant used the drug less often over a three month ...

CHICAGO (Reuters) - The highest dose of an experimental drug developed by Eli Lilly significantly reduced levels of a ...

An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease.

Key Takeaways An experimental drug can delay disability progression in advanced multiple sclerosis patientsTolebrutinib ...

A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

The Eli Lilly drug caused a major drop in the blood levels of Lp(a), but further research is needed to show that it will ...

In an exclusive interview with NBC News, President Donald Trump said there were methods that would allow him to seek a third ...

Eli Lilly’s experimental drug, lepodisiran, reduces lipoprotein(a) (Lp[a]) levels by an average of 93.9 per cent in a ...

Discover how the experimental drug lepodisiran dramatically lowers lipoprotein(a) levels, potentially transforming treatment ...